5 March 2018 EMA/141345/2018 Information Management Division

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use March 2018

This document lists information on applications for centralised marketing authorisation for human medicines that the European Medicines Agency has received for evaluation. It includes the international non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation by the Committee for Medicinal Products for Human Use (CHMP). For generic and biosimilar medicines, it includes the INN (active moiety only, with no information on salt, ester or derivative) and therapeutic area. This list only includes information for medicines whose applications have been validated at the time the report was compiled. The information in this report was compiled on 5 March 2018. Information on designated orphan medicines that are being assessed for marketing authorisation is also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP). Information in bold corresponds to new entries in the monthly list. Entries are removed from this list once the medicine has received a positive or negative opinion from the CHMP or when the applicant has withdrawn the application. The Agency publishes information on these opinions and withdrawn applications on its website. Information on CHMP opinions is also published in the monthly CHMP highlights.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.

Non-orphan medicinal products International non-proprietary name

Therapeutic area

i

(salt, ester, derivative, etc.) / Common Name Abaloparatide

Calcium homeostasis

Abemaciclib

Antineoplastic medicines

Andexanet alfa

Other therapeutic medicines

Apalutamide

Endocrine therapy

Betrixaban

Antithrombotic medicines

Bictegravir / emtricitabine / tenofovir alafenamide (fumarate) Binimetinib

Antivirals for systemic use

Botulinum toxin type A

Muscle relaxants

Brexpiprazole

Psycholeptics

Brigatinib

Antineoplastic medicines

Buprenorphine (hydrochloride)

Other nervous system medicines

Canakinumab

Immunosuppressants

Ciclosporin

Ophthalmologicals

Dacomitinib (monohydrate)

Antineoplastic medicines

Dengue tetravalent vaccine (live, attenuated) Dolutegravir (sodium) /rilpivirine (hydrochloride) Doravirine

Vaccines

Doravirine / lamivudine / tenofovir disoproxil (fumarate) Durvalumab

Antivirals for systemic use

Encorafenib

Antineoplastic medicines

Eravacycline

Antibacterials for systemic use

Erenumab

Analgesics

Fremanezumab

Analgesics

Galcanezumab

Analgesics

Glutamine

Other alimentary tract and metabolism products

Glycopyrronium / formoterol (fumarate dihydrate) Influenza vaccine surface antigen inactivated prepared in cell cultures

Medicines for obstructive airway diseases

Antineoplastic medicines

Antivirals for systemic use Antivirals for systemic use

Antineoplastic medicines

Vaccines

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use EMA/141345/2018

Page 2/5

International non-proprietary name

Therapeutic area

i

(salt, ester, derivative, etc.) / Common Name Lesinurad / allopurinol

Antigout medicines

Lorlatinib

Antineoplastic medicines

Lusutrombopag

Antihemorrhagics

Macimorelin (acetate)

Diagnostic medicines

Melatonin

Psycholeptics

Meropenem (trihydrate) /vaborbactam

Antibacterials for systemic use

Naldemedine (tosilate)

Medicines for constipation

Romosozumab

Medicines for bone diseases

Tildrakizumab

Immunosuppressants

Zanamivir

Antivirals for systemic use

i

Based on the ATC therapeutic sub-group.

Non-orphan generic and biosimilar medicinal products International non-proprietary name /

Therapeutic area

i

Common Name

Total number of applications

Adalimumab

Immunosuppressants

5

Bevacizumab

Antineoplastic medicines

1

Buprenorphine

1

Carmustine

Other nervous system medicines Antineoplastic medicines

Deferiprone

Other therapeutic medicines

1

Doxorubicin

Antineoplastic medicines

1

Gefitinib

Antineoplastic medicines

1

Hydroxycarbamide

Antineoplastic medicines

1

Infliximab

Immunosuppressants

1

Lenalidomide

Immunosuppressants

1

Nitisinone

1

Paclitaxel

Other alimentary tract and metabolism products Antineoplastic medicines

Pegfilgrastim

Immunostimulants

8

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use EMA/141345/2018

1

1

Page 3/5

International non-proprietary name /

Therapeutic area

i

Common Name

Total number of applications

Pemetrexed

Antineoplastic medicines

1

Prasugrel

Antithrombotic medicines

1

Sufentanil

Anesthetics

1

Trastuzumab

Antineoplastic medicines

3

Vigabatrin

Antiepileptics

1

i

Based on the ATC therapeutic sub-group.

Orphan medicinal products

International non-proprietary name (salt, ester,

Therapeutic area

i

derivative, etc.) / Common Name Asparaginase

Antineoplastic medicines

Avacopan

Immunosuppressants

Axicabtagene ciloleucel ii

Antineoplastic medicines

Cannabidiol

Antiepileptics

Caplacizumab

Antithrombotic medicines

Damoctocog alfa pegol

Antihemorrhagics

Daunorubicin (hydrochloride)/ cytarabine ii

Antineoplastic medicines

Entolimod

Immunostimulants

Eteplirsen Inotersen (sodium) ii

Other medicines for disorders of the musculo-skeletal system Other nervous system medicines

Masitinib (mesylate)

Antineoplastic medicines

Metreleptin

Mogamulizumab

Other alimentary tract and metabolism products Other medicines for disorders of the musculo-skeletal system Antineoplastic medicines

Paclitaxel

Antineoplastic medicines

Pacritinib (citrate)

Antineoplastic medicines

Patisiran (sodium) ii

Other nervous system medicines

Ropeginterferon alfa-2b

Immunostimulants

Rucaparib (camsylate)

Antineoplastic medicines

Mexiletine (hcl)

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use EMA/141345/2018

Page 4/5

International non-proprietary name (salt, ester,

Therapeutic area

i

derivative, etc.) / Common Name Sodium benzoate Tezacaftor / ivacaftor

Other alimentary tract and metabolism products Other respiratory system medicines

Tisagenlecleucel ii

Antineoplastic medicines

Treosulfan

Antineoplastic medicines

Trientine (dihydrochloride)

Volanesorsen (sodium)

Other alimentary tract and metabolism products Other alimentary tract and metabolism products Antineoplastic and immunomodulating agents Lipid modifying medicines

Vonicog alfa

Antihemorrhagics

Voretigene neparvovec

Ophthalmologicals

Vestronidase alfa Viable T-cells

i ii

Based on the ATC therapeutic sub-group. Application being reviewed under EMA’s accelerated assessment programme.

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use EMA/141345/2018

Page 5/5

March 2018 - European Medicines Agency - Europa EU

Mar 5, 2018 - it includes the INN (active moiety only, with no information on salt, ester or derivative) and therapeutic area. This list only includes information for medicines whose applications have been validated at the time the report was compiled. The information in this report was compiled on 5 March 2018. Information ...

100KB Sizes 0 Downloads 71 Views

Recommend Documents

March 2018 - European Medicines Agency - Europa EU
Mar 15, 2018 - (Article 5(12) (b) of Regulation (EC) No 141/2000 of the European Parliament and of the Council). When a designated orphan medicinal product receives a positive opinion for marketing authorisation from EMA's Committee for Medicinal Pro

July 2018 - European Medicines Agency - Europa EU
Jul 12, 2018 - An agency of the European Union ... This list only includes information for medicines whose applications have been validated at the time the.

Emtriva - European Medicines Agency - Europa EU
Emtriva is available as capsules (200 mg) and as a solution (10 mg/ml) to be taken by ... The Committee recommended that it be given marketing authorisation.

July 2016 - European Medicines Agency - Europa EU
Jul 11, 2016 - EMA/COMP/451206/2016 ... Cannabidiol for treatment of graft-versus-host disease, Richardson Associates Regulatory ..... Best Regulatory.

EVDAS - European Medicines Agency - Europa EU
EudraVigilance Data Analysis System (EVDAS) users ... Advanced Accelerator Applications ..... ACOM ADVANCED CENTER ONCOLOGY MACERATA SRL.

February 2017 - European Medicines Agency - Europa EU
Mar 16, 2017 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.